[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351506-105":59,"doc-detail-351506-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-mif-cd74-axis-drives-colorectal-cancer-via-glycolytic-reprogramming-and-is-targeted-by-a-novel-small-molecule-inhibitor","The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor","","Macrophage migration inhibitory factor (MIF) promotes inflammation, shapes immune responses, and contributes to chemotherapy resistance within the tumor microenvironment, yet its role in colorectal cancer (CRC) metabolic reprogramming and targeted therapy was unclear. This study integrates multi-omics resources, validates clinical samples, and uses single-cell sequencing plus functional and mechanistic assays. MIF is elevated in CRC, and malignant epithelial cells are the primary source. MIF-CD74 signaling enhances glycolysis and Warburg effect via upregulating HK2, PKM2, and LDHA, while a novel inhibitor F3277-0933 suppresses MIF-driven glycolytic reprogramming and tumor growth.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-mif-cd74-axis-drives-colorectal-cancer-via-glycolytic-reprogramming-and-is-targeted-by-a-novel-small-molecule-inhibitor/351506/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-mif-cd74-axis-drives-colorectal-cancer-via-glycolytic-reprogramming-and-is-targeted-by-a-novel-small-molecule-inhibitor/351506.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",22,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What biological role does MIF play in colorectal cancer according to the study?","Question",{"text":113,"@type":114},"MIF promotes CRC progression by supporting metabolic reprogramming through signaling via CD74, which enhances glycolysis and the Warburg effect. The study connects MIF to inflammation, immune regulation, and treatment resistance within the tumor microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the MIF-CD74 axis drive glycolytic reprogramming?",{"text":118,"@type":114},"MIF binds CD74 and activates downstream signaling that upregulates glycolytic enzymes including HK2, PKM2, and LDHA. This increases glucose uptake and lactate/pyruvate production, shifting metabolism toward the Warburg effect.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the therapeutic approach evaluated in the research?",{"text":122,"@type":114},"The study identifies a novel small-molecule MIF inhibitor, F3277-0933, via virtual screening and validates it in vitro and in vivo. F3277-0933 suppresses MIF-driven glycolytic reprogramming and outperforms the classical inhibitor ISO-1.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351506,1790131855,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":81,"preview_urls":147},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cellular Oncology (2026) 49:81  \n[https://doi.org/10.1007/s13402-026-01202-9](https://doi.org/10.1007/s13402-026-01202-9)  \nRESEARCH  \nThe MIF-CD74 axis drives colorectal cancer via glycolytic  \nreprogramming and is targeted by a novel small-molecule inhibitor  \nJinwei Lou1,2 · Yuhan Chen1,2 · Yue Li1 · Zixuan Liu1 · Shangshang Hu2,3 · Muzi Ding1,2 · Jian Qin2 · Huiling Sun1,2,4 · Yuqin Pan1,2,4  \nReceived: 27 September 2025 / Accepted: 25 March 2026 © The Author(s) 2026  \nAbstract  \nBackground Macrophage migration inhibitory factor (MIF) promotes inflammation, regulates immune responses and chemotherapy resistance in the tumor microenvironment. However, its mechanism of action in colorectal cancer (CRC) metabolic reprogramming and targeted therapeutic potential remain unclear. This study aims to investigate the function, mechanism, and targeted therapeutic potential of MIF in CRC.  \nMethods Data were integrated from TCGA, GTEx, CPTAC, and HPA databases with clinical sample validation. Single-cell sequencing analysis (datasets GSE166555 and GSE144735) was performed, alongside functional assays and mechanistic studies. A novel high-potency MIF inhibitor was identified through virtual screening and validated in vitro and in vivo. Results MIF expression was found to be significantly elevated in CRC tissues and cell lines, correlating with poor overall survival (OS) and disease-specific survival (DSS) . Single-cell sequencing confirmed malignant epithelial cells as the primary MIF source. Functional assays demonstrated that MIF knockout suppressed CRC cell proliferation, migration, and tumor growth in vivo, while MIF overexpression promoted these effects. Mechanistically, MIF binds CD74 to upregulate glycolytic enzymes (HK2, PKM2, LDHA), enhancing glucose uptake and lactate/pyruvate production, thereby driving the Warburg effect and CRC progression. Virtual screening identified a novel high-potency MIF inhibitor, F3277-0933 (IC50 = 8.284 μM) . In vitro and in vivo, F3277-0933 surpassed the classical inhibitor ISO-1 in suppressing MIF-driven glycolytic reprogramming and proliferation.  \nConclusion This study elucidates a novel mechanism by which the MIF-CD74 axis drives CRC progression through glycolytic reprogramming and provides robust preclinical evidence for developing MIF-targeted therapies.  \nJinwei Lou and Yuhan Chen contributed equally to this work and should be considered co-first author.  \n􀀍 Huiling Sun [sunhuiling1988@yeah.net](sunhuiling1988@yeah.net)  \n􀀍 Yuqin Pan [panyuqin@njmu.edu.cn](panyuqin@njmu.edu.cn)  \n1 General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu 211122, China  \n2 General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China  \n3 School of Medicine, Southeast University, Nanjing, Jiangsu 210009, China  \n4 Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211100, China  \n1 3  \nGraphical Abstract  \nThe MIF-CD74 axis drives colorectal cancer progression via glycolytic reprogramming. Extracellular MIF binds to the CD74/CD44 receptor complex on the surface of colorectal cancer cells, initiating downstream signaling cascades. This signal transduction leads to the transcriptional upregulation of key glycolytic enzymes (HK2, PKM2, and LDHA), driving a metabolic switch towards the Warburg effect—characterized by enhanced glucose uptake, increased lactate production (High ECAR), and suppressed mitochondrial oxidative phosphorylation (Low OCR) . This metabolic reprogramming fuels malignant progression. The novel small-molecule inhibitor, F3277-0933, identified via structure-based virtual screening, specifically targets the MIF tautomerase active site. By blocking this oncogenic signaling axis, F3277-0933 effectively reverses the glycolytic phenotype and suppresses tumor growth.  \nKeywords Macrophage migration inhibitory factor (MIF) · Col","cbCaierkHva916PX","https://ap.wps.com/l/cbCaierkHva916PX","pdf",12416675,25,"English","# Abstract\n# Introduction\n## Background and clinical burden of colorectal cancer\n## MIF and CD74 signaling in tumor progression\n# Graphical Abstract\n# Keywords","[{\"question\":\"What biological role does MIF play in colorectal cancer according to the study?\",\"answer\":\"MIF promotes CRC progression by supporting metabolic reprogramming through signaling via CD74, which enhances glycolysis and the Warburg effect. The study connects MIF to inflammation, immune regulation, and treatment resistance within the tumor microenvironment.\"},{\"question\":\"How does the MIF-CD74 axis drive glycolytic reprogramming?\",\"answer\":\"MIF binds CD74 and activates downstream signaling that upregulates glycolytic enzymes including HK2, PKM2, and LDHA. This increases glucose uptake and lactate/pyruvate production, shifting metabolism toward the Warburg effect.\"},{\"question\":\"What is the therapeutic approach evaluated in the research?\",\"answer\":\"The study identifies a novel small-molecule MIF inhibitor, F3277-0933, via virtual screening and validates it in vitro and in vivo. F3277-0933 suppresses MIF-driven glycolytic reprogramming and outperforms the classical inhibitor ISO-1.\"}]","The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor | PDF",1790094477,63,[148,152,156],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/b8e9ad4718c9905c46a4f1d3dc889331.webp",983,1306,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/9b0029294c56cc4f53f8b27c0173cef1.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ea66ef9aded2d1c61774d30e08fd89d4.webp",981,1303]